These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32322662)

  • 1. Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.
    Cervera-Carrascon V; Quixabeira DCA; Havunen R; Santos JM; Kutvonen E; Clubb JHA; Siurala M; Heiniö C; Zafar S; Koivula T; Lumen D; Vaha M; Garcia-Horsman A; Airaksinen AJ; Sorsa S; Anttila M; Hukkanen V; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2020 Jun; 17():47-60. PubMed ID: 32322662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
    Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
    Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.
    Havunen R; Siurala M; Sorsa S; Grönberg-Vähä-Koskela S; Behr M; Tähtinen S; Santos JM; Karell P; Rusanen J; Nettelbeck DM; Ehrhardt A; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2017 Mar; 4():77-86. PubMed ID: 28345026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.
    Siurala M; Vähä-Koskela M; Havunen R; Tähtinen S; Bramante S; Parviainen S; Mathis JM; Kanerva A; Hemminki A
    Oncoimmunology; 2016 May; 5(5):e1136046. PubMed ID: 27467954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
    Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.
    Havunen R; Kalliokoski R; Siurala M; Sorsa S; Santos JM; Cervera-Carrascon V; Anttila M; Hemminki A
    Cells; 2021 Jan; 10(2):. PubMed ID: 33513935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
    Santos JM; Cervera-Carrascon V; Havunen R; Zafar S; Siurala M; Sorsa S; Anttila M; Kanerva A; Hemminki A
    Mol Ther; 2018 Sep; 26(9):2243-2254. PubMed ID: 30017877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.
    Havunen R; Santos JM; Sorsa S; Rantapero T; Lumen D; Siurala M; Airaksinen AJ; Cervera-Carrascon V; Tähtinen S; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2018 Dec; 11():109-121. PubMed ID: 30569015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.
    Kudling TV; Clubb JHA; Quixabeira DCA; Santos JM; Havunen R; Kononov A; Heiniö C; Cervera-Carrascon V; Pakola S; Basnet S; Grönberg-Vähä-Koskela S; Arias V; Gladwyn-Ng I; Aro K; Bäck L; Räsänen J; Ilonen I; Borenius K; Räsänen M; Hemminki O; Rannikko A; Kanerva A; Tapper J; Hemminki A
    Oncoimmunology; 2022; 11(1):2096572. PubMed ID: 35845722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
    Quixabeira DCA; Zafar S; Santos JM; Cervera-Carrascon V; Havunen R; Kudling TV; Basnet S; Anttila M; Kanerva A; Hemminki A
    Front Immunol; 2021; 12():674400. PubMed ID: 34084172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.
    Heiniö C; Clubb J; Kudling T; Quixabeira D; Cervera-Carrascon V; Havunen R; Grönberg-Vähä-Koskela S; Santos JM; Tapper J; Kanerva A; Hemminki A
    Diseases; 2022 Aug; 10(3):. PubMed ID: 35997357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling.
    Heiniö C; Havunen R; Santos J; de Lint K; Cervera-Carrascon V; Kanerva A; Hemminki A
    Cells; 2020 Mar; 9(4):. PubMed ID: 32225009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.
    Quixabeira DCA; Jirovec E; Pakola S; Havunen R; Basnet S; Santos JM; Kudling TV; Clubb JHA; Haybout L; Arias V; Grönberg-Vähä-Koskela S; Cervera-Carrascon V; Pasanen A; Anttila M; Tapper J; Kanerva A; Hemminki A
    Cancer Gene Ther; 2023 Nov; 30(11):1543-1553. PubMed ID: 37666898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.
    Basnet S; Santos JM; Quixabeira DCA; Clubb JHA; Grönberg-Vähä-Koskela SAM; Arias V; Pakola S; Kudling TV; Heiniö C; Havunen R; Cervera-Carrascon V; Sorsa S; Anttila M; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2023 Mar; 28():59-73. PubMed ID: 36699617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ.
    Ye K; Li F; Wang R; Cen T; Liu S; Zhao Z; Li R; Xu L; Zhang G; Xu Z; Deng L; Li L; Wang W; Stepanov A; Wan Y; Guo Y; Li Y; Wang Y; Tian Y; Gabibov AG; Yan Y; Zhang H
    Mol Ther; 2022 Dec; 30(12):3658-3676. PubMed ID: 35715953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
    Taguchi S; Fukuhara H; Todo T
    Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
    Bramante S; Koski A; Kipar A; Diaconu I; Liikanen I; Hemminki O; Vassilev L; Parviainen S; Cerullo V; Pesonen SK; Oksanen M; Heiskanen R; Rouvinen-Lagerström N; Merisalo-Soikkeli M; Hakonen T; Joensuu T; Kanerva A; Pesonen S; Hemminki A
    Int J Cancer; 2014 Aug; 135(3):720-30. PubMed ID: 24374597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
    Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.